Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Non Operating Income (2019 - 2025)

Inmune Bio's Non Operating Income history spans 7 years, with the latest figure at $961000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income rose 397.93% year-over-year to $961000.0; the TTM value through Sep 2025 reached $1.5 million, up 1236.64%, while the annual FY2024 figure was $553000.0, 307.12% up from the prior year.
  • Non Operating Income for Q3 2025 was $961000.0 at Inmune Bio, up from $113000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.7 million in Q4 2021 and bottomed at -$2.5 million in Q4 2022.
  • The 5-year median for Non Operating Income is $119000.0 (2024), against an average of $128473.7.
  • The largest annual shift saw Non Operating Income skyrocketed 43225.0% in 2021 before it plummeted 244.55% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $1.7 million in 2021, then tumbled by 244.55% to -$2.5 million in 2022, then surged by 82.63% to -$435000.0 in 2023, then skyrocketed by 157.24% to $249000.0 in 2024, then skyrocketed by 285.94% to $961000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Non Operating Income are $961000.0 (Q3 2025), $113000.0 (Q2 2025), and $166000.0 (Q1 2025).